Acne News and Research

Latest Acne News and Research

Aphios awarded US patent for compositions, methods for treating diseases involving 5-α reductase enzyme

Aphios® Corporation today announced that it was awarded United States Patent No. 7,744,935 B2 for "Compositions and Methods for Inhibiting 5-α Reductase," granted June 29, 2010. This invention is related to compositions and methods for treating diseases involving the 5-alpha (α) reductase enzyme.

28 Jul 2010

Researchers reveal biological rationale for why corticosteroids help people with lupus

Researchers at UT Southwestern Medical Center have uncovered the biological rationale for why large doses of corticosteroids given repeatedly over several weeks may help individuals with lupus, a chronic inflammatory disease that affects more than 1 million people in the U.S.

27 Jul 2010

FDA approves Mylan's ANDA for generic Solodyn ER tablets for acne treatment

Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited received final approval on July 20 from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Minocycline Hydrochloride Extended Release Tablets (Minocycline ER), 45 mg, 90 mg and 135 mg, the generic version of Solodyn® ER, a treatment for acne, sold by Medicis Pharmaceuticals Corporation (Medicis). Mylan Pharmaceuticals Inc. commenced immediate shipment of the product after approval.

23 Jul 2010

AlexTriVantage pigment-specific lasers for multi-colored tattoo removal

In the past, the only options for removing tattoos were dermabrasion and excision – neither was entirely effective and both were painful. But thanks to the latest advancements in science and technology, there are now pigment-specific lasers that can target more colors than ever before.

22 Jul 2010

NovaBay reports positive results from NVC-422 Phase 2a proof-of-concept clinical trial for impetigo

NovaBay Pharmaceuticals, Inc. today announced that its lead product candidate was safe and efficacious against the highly contagious skin infection impetigo in a Phase 2a proof-of-concept clinical trial. This dose-ranging study showed that the drug cleared impetigo infections, including those in the trial caused by a drug-resistant strain of bacteria called methicillin-resistant Staphylococcus aureus or MRSA. Impetigo afflicts approximately 1 million people, primarily infants and children, in the United States annually.

21 Jul 2010

Sinobiopharma, Xianfeng enter agreement to manufacture, co-market Clindamycin and L-alanyl-L-glutamine

Sinobiopharma, Inc. is pleased to announce that it has signed an agreement with Anhui Xianfeng Pharmaceuticals Co., Ltd to manufacture and co-market Clindamycin, an antibiotic, and L-alanyl-L-glutamine, a parenteral nutrition.

21 Jul 2010

JDD publishes long-term efficacy and tolerability study of PyratineXR Moisturizing Lotion

The June 2010 issue of Journal of Drugs in Dermatology (JDD), a full-color, peer-reviewed publication serving the dermatology community, features a study on the long-term efficacy and tolerability of the active ingredient in PyratineXR™.

16 Jul 2010

NovaBay Pharmaceuticals issued Notice of Allowance for broad portfolio of anti-infective compounds

NovaBay Pharmaceuticals, Inc. announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office on a patent application for a broad portfolio of anti-infective compounds, including NVC-612. The patent will broaden protection for NovaBay's first-in-class Aganocide family of compounds, which are designed to fight infections without causing drug resistance.

15 Jul 2010

Collagen Induction Therapy and Ultrasonic Microdermabrasion demonstrations at Lecada's open house

An open house on Thursday, June 17th, celebrated Lecada Medical Artistry's grand opening at 3710 West Azeele Street, Tampa. Lecada offers innovative treatments for face and body that provide aesthetic and anti-aging solutions designed to help you look and feel your best.

14 Jul 2010

Rohto launches AFC Medirepair with Signum's compound Arazine in Japan

Signum Biosciences announced that its partner, Rohto Pharmaceutical Co., Ltd., has launched AFC Medirepair® with Signum's compound Arazine™ (n-acetyl-s-farnsylcysteine or AFC) in Japan. Arazine™ is the first compound from Signum's novel anti-inflammatory platform to be commercialized from Signum's pipeline of Signal Transduction Modulators (STMs).

12 Jul 2010

Tips on skin care

Your skin protects you, heals itself and lasts a lifetime. Find how to give it some skin care in return, to help keep it looking and feeling its best.

12 Jul 2010

PhotoMedex receives multi-million dollar order from AMICO Group to purchase XTRAC laser systems

PhotoMedex, Inc. announced that the Company has received from AMICO Group, its distributor in the Middle East, a multi-million dollar order to purchase XTRAC laser systems that will be installed in hospitals throughout the Kingdom of Saudi Arabia. The order includes customary terms and conditions, including advanced payments and letters of credit covering the purchase order. Delivery is expected to be in the third and fourth quarters of this year.

8 Jul 2010

Cipher Pharmaceuticals reaches cumulative sales milestone for Lipofen

Cipher Pharmaceuticals Inc. today announced that it reached a cumulative sales milestone for Lipofen, the Company's fenofibrate product. Achieving this target triggers a US$1.0 million milestone payment from Kowa Pharmaceuticals America Inc., Cipher's U.S. marketing and distribution partner, which will be reflected in Cipher's revenue for the second quarter of fiscal 2010.

7 Jul 2010

Retin-A Micro Pump combines tretinoin for treating acne: Study

From the minute they wake until the minute they sleep, today's teenagers have busy, demanding schedules. Life may be hectic, but an acne care routine doesn't have to get in the way, according to a new study published in the July 2010 issue of Journal of Drugs in Dermatology.

7 Jul 2010

FDA grants Fougera first generic approval for Adapalene Cream 0.1%

E. Fougera & Co., a leading specialty pharmaceutical manufacturer, announced it has received first generic approval from the FDA for Adapalene Cream 0.1% (Rx). Fougera's Adapalene Cream 0.1% is rated AB, generically equivalent to Differin® by Galderma Pharmaceuticals. According to industry data, U.S. sales of the brand named product in 2009 exceeded $55 million. This approval also marks the fourth product approval that the FDA has granted to Fougera this year.

7 Jul 2010

Survey: 66% of patients with metastatic colorectal cancer are now tested for KRAS

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, has revealed new results from a global survey demonstrating that 66% of patients with metastatic colorectal cancer (mCRC) are now tested for KRAS to determine if they could benefit from a personalized therapy, such as Erbitux® (cetuximab). This represents a 50% increase in levels of KRAS testing in just one year.

1 Jul 2010

Twelve residents receive one-year fellowship grant to study medical dermatology

Twelve dermatology residents from leading medical schools around the country each received a $40,000, one-year fellowship grant to study medical dermatology. The fellowships, awarded by the National Psoriasis Foundation, provide support to eligible institutions to develop and enhance opportunities for physicians training for careers in medical dermatology.

1 Jul 2010

Vicept completes $16 million Series A financing

Vicept™ Therapeutics Inc., a privately held specialty biopharmaceutical company dedicated to developing the first effective topically applied therapy for erythema (facial redness) of rosacea, announced that it has secured $10 million to complete a total $16 million Series A financing. The Series A was led by Vivo Ventures, Sofinnova Ventures and Fidelity Biosciences.

30 Jun 2010

Health Canada approves Solta Medical's Thermage CPT, Fraxel re:store Dual systems

Solta Medical, Inc., the pioneer in fractional resurfacing and non-invasive skin tightening and a market leader in aesthetic skin treatments, today announced Health Canada approval of its Thermage CPT™ and Fraxel re:store® Dual systems. These products are now available to physicians in Canada. In the fall of 2009, the company received U.S. FDA clearance to market and sell both the Thermage CPT and Fraxel re:store Dual systems. Both systems are now available in over 100 countries worldwide.

28 Jun 2010

ULURU, Strakan International divest interest in Zindaclin to Crawford Healthcare subsidiary

ULURU Inc. announced today that Strakan International Limited and ULURU have divested their respective interest in Zindaclin® to a subsidiary of Crawford Healthcare Limited, a pharmaceutical company based in England. Zindaclin® is a product for the treatment of acne which is outside the strategic focus of ULURU. This product was included in the technology package ULURU acquired when it was formed in 2005.

28 Jun 2010

Acne News and Research

Latest Acne News and Research

Aphios awarded US patent for compositions, methods for treating diseases involving 5-α reductase enzyme

Researchers reveal biological rationale for why corticosteroids help people with lupus

FDA approves Mylan's ANDA for generic Solodyn ER tablets for acne treatment

AlexTriVantage pigment-specific lasers for multi-colored tattoo removal

NovaBay reports positive results from NVC-422 Phase 2a proof-of-concept clinical trial for impetigo

Sinobiopharma, Xianfeng enter agreement to manufacture, co-market Clindamycin and L-alanyl-L-glutamine

JDD publishes long-term efficacy and tolerability study of PyratineXR Moisturizing Lotion

NovaBay Pharmaceuticals issued Notice of Allowance for broad portfolio of anti-infective compounds

Collagen Induction Therapy and Ultrasonic Microdermabrasion demonstrations at Lecada's open house

Rohto launches AFC Medirepair with Signum's compound Arazine in Japan

Tips on skin care

PhotoMedex receives multi-million dollar order from AMICO Group to purchase XTRAC laser systems

Cipher Pharmaceuticals reaches cumulative sales milestone for Lipofen

Retin-A Micro Pump combines tretinoin for treating acne: Study

FDA grants Fougera first generic approval for Adapalene Cream 0.1%

Survey: 66% of patients with metastatic colorectal cancer are now tested for KRAS

Twelve residents receive one-year fellowship grant to study medical dermatology

Vicept completes $16 million Series A financing

Health Canada approves Solta Medical's Thermage CPT, Fraxel re:store Dual systems

ULURU, Strakan International divest interest in Zindaclin to Crawford Healthcare subsidiary

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Acne News and Research

Latest Acne News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in